Dongsheng obtains exclusive sales rights of Thymosin Alpha 1 Injection in China

Dongsheng Pharmaceutical International Co., Ltd. announced today that it has obtained the exclusive sales rights of Thymosin Alpha 1 Injection in 19 provinces in China from Shanghai Biochemistry Pharmaceutical Co. I.

The State Food and Drug Administration of China (the "SFDA") approved the manufacturing permit of Thymosin Alpha 1 Injection for Shanghai Biochemistry Pharmaceutical Co. I on June 29, 2010. Immediately after such approval, Shanghai Biochemistry submitted the manufactured samples to the SFDA for quality check, which is a necessary step to receive final approval for mass manufacturing. We expect that the samples will pass the quality check in the next 3-6 months, at which time Thymosin Alpha 1 Injection will be granted final approval for mass manufacturing.

Thymosin Alpha 1 Injection is an immune modifier that has been proven to be effective in the treatment of chronic hepatitis B, acute severe hepatitis, adjuvant therapy for tumor and immuno compromised diseases. Thymosin Alpha 1 Injection has been admitted into the China National Basic Medicine Coverage List, thereby making it more affordable to consumers and potentially increasing its demand.  In June 2010, Dongsheng commenced a marketing campaign for Thymosin Alpha 1 Injection within its sales and distribution network, and the response so far from potential customers has been promising.

Mr. Zhu XiaoDong, CEO of Dongsheng Pharmaceutical International, stated that, "Thymosin Alpha 1 is a high value and high margin medicine.  Obtaining exclusive sales rights for this product in 19 provinces represents another milestone that Dongsheng Pharmaceutical has accomplished since it went public in March 2010."